ASCO 2014:MACC1基因对人胃癌淋巴管生成的影响

2014-05-31 刘揆亮 译 医学论坛网

结肠癌转移相关基因-1对人胃癌淋巴管生成的影响 摘要号:#4042 第一作者:Sun Li,南方医科大学南方医院 背景:结肠癌转移相关基因-1(MACC1)是一种新型癌基因,主要表达于包括胃癌(GC)在内的几种实体瘤,与肿瘤淋巴结转移有关。GC的淋巴结转移对患者的临床转归有关键决定作用。因此,我们的研究评价了MACC1是否影响GC淋巴管转移,并探讨了其可能机制

结肠癌转移相关基因-1对人胃癌淋巴管生成的影响

摘要号:#4042

第一作者:Sun Li,南方医科大学南方医院

背景:结肠癌转移相关基因-1(MACC1)是一种新型癌基因,主要表达于包括胃癌(GC)在内的几种实体瘤,与肿瘤淋巴结转移有关。GC的淋巴结转移对患者的临床转归有关键决定作用。因此,我们的研究评价了MACC1是否影响GC淋巴管转移,并探讨了其可能机制。

方法:在190例GC组织中进行了MACC1和LVYE-1的免疫组化分析以发现MACC1与淋巴结转移以及淋巴管生成之间的关系。采用MTT、Transwell迁移和3D培养检测评价了MACC1上清液与人淋巴管内皮细胞(HLEC)共培养后对其增殖、迁移和毛细血管样结构形成能力的影响。另外,我们采用qRT-PCR、免疫印迹和ELISA 检测了GC细胞内血管内皮生长因子-C (VEGF-C)/VEGF-D的表达。

结果:MACC1的表达与淋巴结转移(p<0.01)和淋巴管生成(p<0.001)相关,同时,MACC1表达缺失与GC患者预后较好相关(p<0.001)。此外,体外研究证实 MACC1通过促进细胞增殖和迁移上调HLEC的管状结构形成能力。在裸鼠种植试验中,MACC1 还可促进淋巴管生成和淋巴侵袭。另外,MACC1在GC细胞和移植瘤中从蛋白和基因水平均显著上调VEGF-C/VEGF-D,肝细胞生长因子(HGF)/c-Met信号轴抑制剂可抑制这种作用。

结论:这些数据证实MACC1上调VEGF-C/VEGF-D表达,部分通过HGF/c-Met途径促进淋巴管生成,提示MACC1在胃癌淋巴结转移中具有关键作用。

研究链接:Effect of metastasis associated in colon cancer-1 on lymphangiogenesis in human gastric cancer. (Abstract 4042)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1938330, encodeId=db091938330cc, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Apr 06 08:39:00 CST 2015, time=2015-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937096, encodeId=5e34193e09684, content=<a href='/topic/show?id=9d8c659e83e' target=_blank style='color:#2F92EE;'>#淋巴管生成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65978, encryptionId=9d8c659e83e, topicName=淋巴管生成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Fri Nov 21 10:39:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995896, encodeId=3418199589627, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Jan 16 14:39:00 CST 2015, time=2015-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324936, encodeId=029d132493656, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Jun 02 12:39:00 CST 2014, time=2014-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529343, encodeId=f3fe152934347, content=<a href='/topic/show?id=4735659e3cf' target=_blank style='color:#2F92EE;'>#淋巴管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65973, encryptionId=4735659e3cf, topicName=淋巴管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee7311933759, createdName=amyloid, createdTime=Mon Jun 02 12:39:00 CST 2014, time=2014-06-02, status=1, ipAttribution=)]
    2015-04-06 quxin068
  2. [GetPortalCommentsPageByObjectIdResponse(id=1938330, encodeId=db091938330cc, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Apr 06 08:39:00 CST 2015, time=2015-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937096, encodeId=5e34193e09684, content=<a href='/topic/show?id=9d8c659e83e' target=_blank style='color:#2F92EE;'>#淋巴管生成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65978, encryptionId=9d8c659e83e, topicName=淋巴管生成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Fri Nov 21 10:39:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995896, encodeId=3418199589627, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Jan 16 14:39:00 CST 2015, time=2015-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324936, encodeId=029d132493656, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Jun 02 12:39:00 CST 2014, time=2014-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529343, encodeId=f3fe152934347, content=<a href='/topic/show?id=4735659e3cf' target=_blank style='color:#2F92EE;'>#淋巴管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65973, encryptionId=4735659e3cf, topicName=淋巴管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee7311933759, createdName=amyloid, createdTime=Mon Jun 02 12:39:00 CST 2014, time=2014-06-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1938330, encodeId=db091938330cc, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Apr 06 08:39:00 CST 2015, time=2015-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937096, encodeId=5e34193e09684, content=<a href='/topic/show?id=9d8c659e83e' target=_blank style='color:#2F92EE;'>#淋巴管生成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65978, encryptionId=9d8c659e83e, topicName=淋巴管生成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Fri Nov 21 10:39:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995896, encodeId=3418199589627, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Jan 16 14:39:00 CST 2015, time=2015-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324936, encodeId=029d132493656, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Jun 02 12:39:00 CST 2014, time=2014-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529343, encodeId=f3fe152934347, content=<a href='/topic/show?id=4735659e3cf' target=_blank style='color:#2F92EE;'>#淋巴管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65973, encryptionId=4735659e3cf, topicName=淋巴管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee7311933759, createdName=amyloid, createdTime=Mon Jun 02 12:39:00 CST 2014, time=2014-06-02, status=1, ipAttribution=)]
    2015-01-16 yb6560
  4. [GetPortalCommentsPageByObjectIdResponse(id=1938330, encodeId=db091938330cc, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Apr 06 08:39:00 CST 2015, time=2015-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937096, encodeId=5e34193e09684, content=<a href='/topic/show?id=9d8c659e83e' target=_blank style='color:#2F92EE;'>#淋巴管生成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65978, encryptionId=9d8c659e83e, topicName=淋巴管生成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Fri Nov 21 10:39:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995896, encodeId=3418199589627, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Jan 16 14:39:00 CST 2015, time=2015-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324936, encodeId=029d132493656, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Jun 02 12:39:00 CST 2014, time=2014-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529343, encodeId=f3fe152934347, content=<a href='/topic/show?id=4735659e3cf' target=_blank style='color:#2F92EE;'>#淋巴管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65973, encryptionId=4735659e3cf, topicName=淋巴管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee7311933759, createdName=amyloid, createdTime=Mon Jun 02 12:39:00 CST 2014, time=2014-06-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1938330, encodeId=db091938330cc, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Apr 06 08:39:00 CST 2015, time=2015-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937096, encodeId=5e34193e09684, content=<a href='/topic/show?id=9d8c659e83e' target=_blank style='color:#2F92EE;'>#淋巴管生成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65978, encryptionId=9d8c659e83e, topicName=淋巴管生成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Fri Nov 21 10:39:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995896, encodeId=3418199589627, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Jan 16 14:39:00 CST 2015, time=2015-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324936, encodeId=029d132493656, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Jun 02 12:39:00 CST 2014, time=2014-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529343, encodeId=f3fe152934347, content=<a href='/topic/show?id=4735659e3cf' target=_blank style='color:#2F92EE;'>#淋巴管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65973, encryptionId=4735659e3cf, topicName=淋巴管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee7311933759, createdName=amyloid, createdTime=Mon Jun 02 12:39:00 CST 2014, time=2014-06-02, status=1, ipAttribution=)]
    2014-06-02 amyloid

相关资讯

ASCO 2014:结节型病变是口腔粘膜黑色素瘤的危险信号

摘要号:#6058 第一作者:郭伟,上海交通大学医学院附属第九人民医院口腔颌面外科 背景:口腔粘膜黑色素瘤(OMM)经常转移至颈部淋巴结。虽然为评估颈淋巴结清除术治疗OMM的疗效已进行了大量研究,但该领域依然存在相当多的争议。 方法:对1998年1月至2012年7月期间254 例OMM患者的临床特点、治疗和预后情况进行回顾性分析;并进行多变量分析,以确定与总生

ASCO 2014:中国胃癌HER2表达与Lauren分型的关系

摘要号:#4065 第一作者:徐瑞华,中山大学肿瘤防治中心 背景:肠型胃癌预后好于弥漫型胃癌,且肠型胃癌HER2阳性率较高。不过HER2的预后价值仍有争议。可能存在一些影响HER2生存预测价值的因素。HER2表达与Lauren分型之间的关系如何?我们还将在不同HER2表达状况和Lauren分型的胃癌患者中分析生存差异。 方法:全部患者通过免疫组织化学(IHC)

ASCO 2014:Bev+DOF可降低局部进展期胃癌的TN分期

局部进展期胃癌(LAGC)新辅助贝伐珠单抗(Bev)加DOF与DOF后R0切除的比较及其与循环肿瘤细胞(CTC)的关系 摘要号:#4043 第一作者:杜楠,中国人民解放军总医院第一附属医院肿瘤内科 背景:局部进展期胃癌(LAGC)通过R0切除可能治愈,新辅助化疗可部分提高R0切除率。贝伐珠单抗(Bev)是一种抗肿瘤血管生成的单克隆抗体,在进展期GC中与化疗联合时治疗有效。另外

ASCO 2014:韩宝惠谈第三代EGFR抑制剂对NSCLC的疗效

题目:EGFR抑制剂耐药的非小细胞肺癌(NSCLC)患者中应用突变选择性EGFR抑制剂AZD9291的临床活性(Clinical activity of the mutant selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor resistant non-small cell lung cancer (NS

ASCO 2014:局部进展期是食管鳞癌术前新辅助放化疗优于术后

新辅助治疗与辅助治疗相比哪种治疗对于可切除的局部进展期食管鳞状细胞癌更为有效? 摘要号:#4060 第一作者:陈奇勋,浙江省肿瘤医院胸部肿瘤外科 背景:中国针对食管鳞状细胞癌(ESCC)的主要治疗为手术联合术后辅助放化疗。术前新辅助放化疗治疗的作用没有得到充分明确。我们在中国的一个ESCC人群中对新辅助放化疗后手术治疗及手术治疗后辅助放化疗的作用进行了比较。

ASCO 2014:江泽飞:早期乳腺癌双靶向预防复发研究(ALTTO研究)

“不大不小的好消息”:早期乳腺癌双靶向预防复发研究题目:早期HER2阳性乳腺癌中对比拉帕替尼(L)单药,曲妥珠单抗(T)单药,二者序贯(T→L)或联合(T+L)抗HER2辅助治疗1年的Ⅲ期ALTTO试验首次结果(First results from the phase Ⅲ ALTTO trial comparing one year of anti-HER2 therapy with la